BR112019002204A8 - composições de reelin para tratamento de distúrbios neurológicos - Google Patents

composições de reelin para tratamento de distúrbios neurológicos

Info

Publication number
BR112019002204A8
BR112019002204A8 BR112019002204A BR112019002204A BR112019002204A8 BR 112019002204 A8 BR112019002204 A8 BR 112019002204A8 BR 112019002204 A BR112019002204 A BR 112019002204A BR 112019002204 A BR112019002204 A BR 112019002204A BR 112019002204 A8 BR112019002204 A8 BR 112019002204A8
Authority
BR
Brazil
Prior art keywords
reelin
repeat
syndrome
full
region
Prior art date
Application number
BR112019002204A
Other languages
English (en)
Other versions
BR112019002204A2 (pt
Inventor
J Weeber Edwin
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida filed Critical Univ South Florida
Publication of BR112019002204A2 publication Critical patent/BR112019002204A2/pt
Publication of BR112019002204A8 publication Critical patent/BR112019002204A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)

Abstract

alterações nos níveis de reelin, bem como a sinalização de reelin, alteram a função cognitiva. isto pode ser conseguido administrando uma quantidade terapeuticamente eficaz de uma repetição fragmento de reelin, ou uma construção formada de repetições de fragmento de reelin para um paciente ou sujeito. alterações nos níveis de reelin podem ser usadas para tratar várias doenças neurodegenerativas, insultos neuronais, ou acidente vascular cerebral, como síndrome do x frágil, síndrome de william, síndrome rett, síndrome de down, síndrome de angelman, autismo, isquemia, hipóxia, doença de alzheimer e esquizofrenia. reelin também pode ser usado para alterar a densidade da espinha dendrítica, diminuída a longo prazo potenciação e plasticidade sináptica diminuída e déficits de aprendizagem associativa. construções formadas a partir da região de repetição 3 de reelin de comprimento total e região de repetição 5 de comprimento total de reelin, ou repita a região 3 de comprimento total de reelin e repita a região 6 de comprimento total de reelin foi encontrado particularmente útil.
BR112019002204A 2016-08-03 2017-08-03 composições de reelin para tratamento de distúrbios neurológicos BR112019002204A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662370519P 2016-08-03 2016-08-03
US201762486729P 2017-04-18 2017-04-18
PCT/US2017/045307 WO2018027037A2 (en) 2016-08-03 2017-08-03 Reelin compositions for treatment of neurological disorders

Publications (2)

Publication Number Publication Date
BR112019002204A2 BR112019002204A2 (pt) 2019-07-09
BR112019002204A8 true BR112019002204A8 (pt) 2019-10-01

Family

ID=61073666

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019002204A BR112019002204A8 (pt) 2016-08-03 2017-08-03 composições de reelin para tratamento de distúrbios neurológicos

Country Status (13)

Country Link
US (1) US20190169246A1 (pt)
EP (1) EP3506927A4 (pt)
JP (1) JP7253800B2 (pt)
KR (1) KR102523237B1 (pt)
CN (1) CN109715194B (pt)
AU (1) AU2017306558A1 (pt)
BR (1) BR112019002204A8 (pt)
CA (1) CA3032697A1 (pt)
CO (1) CO2019001060A2 (pt)
IL (1) IL264603B2 (pt)
MX (1) MX2019001421A (pt)
NZ (1) NZ750291A (pt)
WO (1) WO2018027037A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021146713A1 (en) * 2020-01-17 2021-07-22 University Of South Florida Methods of treating fragile x syndrome with reelin
WO2023288325A2 (en) * 2021-07-16 2023-01-19 Ptc Therapeutics Inc. Recombinant reelin gene therapy
KR20240007846A (ko) 2022-07-08 2024-01-17 재단법인대구경북과학기술원 Ｒｅｅｌｉｎ을 발현하는 신경세포의 대량생산방법
WO2024081934A1 (en) * 2022-10-13 2024-04-18 The General Hospital Corporation Compositions and methods using reelin in alzheimer's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323177B1 (en) * 1999-06-16 2001-11-27 St. Jude Children's Research Hospital Interaction of reelin with very low density lipoprotein (VLDL) receptor for screening and therapies
US7510850B2 (en) * 2005-11-10 2009-03-31 Carnegie Institution Of Washington Isolation of the mitotic spindle matrix and its methods of use
WO2010091399A2 (en) * 2009-02-09 2010-08-12 University Of South Florida Reelin rescues cognitive function
US20150183850A1 (en) 2012-05-18 2015-07-02 University Of Iowa Research Foundation Methods and compositions for treating amyloid deposits
MX2015005722A (es) 2012-11-05 2016-01-12 Genzyme Corp Composiciones y metodos para el tratamiento de proteinopatias.
ES2859605T3 (es) 2013-07-26 2021-10-04 Univ Iowa Res Found Procedimientos y composiciones para tratar enfermedades del cerebro
EP3233131A1 (en) 2014-12-16 2017-10-25 Board of Regents of the University of Nebraska Gene therapy for juvenile batten disease

Also Published As

Publication number Publication date
CA3032697A1 (en) 2018-02-08
KR20190035842A (ko) 2019-04-03
CN109715194A (zh) 2019-05-03
JP2019524775A (ja) 2019-09-05
BR112019002204A2 (pt) 2019-07-09
IL264603B2 (en) 2023-10-01
US20190169246A1 (en) 2019-06-06
NZ750291A (en) 2021-07-30
IL264603B1 (en) 2023-06-01
IL264603A (en) 2019-02-28
WO2018027037A2 (en) 2018-02-08
EP3506927A2 (en) 2019-07-10
EP3506927A4 (en) 2020-05-06
MX2019001421A (es) 2019-09-04
JP7253800B2 (ja) 2023-04-07
AU2017306558A1 (en) 2019-02-21
CN109715194B (zh) 2024-06-11
CO2019001060A2 (es) 2019-02-19
KR102523237B1 (ko) 2023-04-18
WO2018027037A3 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
BR112019002204A8 (pt) composições de reelin para tratamento de distúrbios neurológicos
BR112018000041A2 (pt) Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl
WO2018060732A3 (en) Compositions and methods for treating seizure disorders
MX2019004616A (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
AR110747A1 (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo
ECSP19048477A (es) Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades
CY1116699T1 (el) Παραγωγα αλφα-αμινοαμιδιου τα οποια ειναι χρησιμα στην αγωγη γνωστικων διαταραχων
UY39413A (es) Compuestos inhibidores de metaloenzimas
BR112016011483A2 (pt) Derivados de imidazotriazina como moduladores de atividade de tnf
BR112018003250A2 (pt) compostos deuterados e usos dos mesmos
EA201490697A1 (ru) Белки с двойной функцией для лечения метаболических расстройств
BR112016011485A2 (pt) Derivados de imidazopiridazina como moduladores de atividade de tnf
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
UY28817A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegerativos
UY33206A (es) Métodos de tratamiento de enfermedades autoinmunes con antagonistas de dll4
BR112014003704A2 (pt) moduladores ror gama
EA201691602A1 (ru) Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройств
EA201400969A1 (ru) Новые терапевтические подходы для лечения болезни паркинсона
GT201100336A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
BR112016012258A2 (pt) Derivados de tetra-hidrobenzimidazol como moduladores de atividade de tnf
BR112015017929A2 (pt) di-hidropirimidinonas bicíclicas substituídas e seu uso como inibidores de atividade elastase neutrófila
EA201492102A1 (ru) Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
CL2020001495A1 (es) Composiciones y método para el tratamiento de enfermedades metabólicas
ECSP19021843A (es) Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: PARA QUE SEJA ACEITA A PETICAO DE EXAME NO 800190290886 DE 01/08/2019 (GRU 29409161907790364) APRESENTE COMPLEMENTACAO DA RETRIBUICAO DE EXAME PARA VALOR DE 15 REIVINDICACOES SEM DESCONTO, UMA VEZ QUE FOI RECOLHIDO O VALOR PARA 10 REIVINDICACOES E O DEPOSITANTE NAO FAZ JUS AO DESCONTO, CONFORME TABELA VIGENTE.

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]